No significant associations were observed between CDKN2A hypermethylation and other clinicopathological features [58], indicating the relevance of CDKN2A hypermethylation, specifically to lymph node metastasis and survival outcomes. This evidence concerns the gene CDKN2A and metastatic malignant neoplasm in the lymph nodes.